anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The experience sampling method (ESM) is a structured diary technique, which is used to assess thoughts, mood and appraise subjective experiences in daily life. It has been recognized as a useful tool for understanding the characteristics, dynamics, and underlying mechanisms of prodromal symptoms of psychosis. The present systematic review aimed to provide a qualitative synthesis of findings provided by the ESM studies conducted in people with psychosis risk states. A systematic review of the MEDLINE, ERIC, Academic Search Ultimate, and Health Source: Nursing/Academic Edition databases, utilizing search terms related to the ESM and the risk of psychosis was conducted. Out of 1069 publication records identified, 77 studies met the inclusion criteria for the review. Data were synthesized around the following topics: 1) assessment of symptoms dynamics and social functioning; 2) assessment of the mechanisms contributing to the emergence of psychotic experiences and 3) assessment of stress sensitivity. The studies have shown that negative emotions are associated with subsequent development of paranoia. The tendency to draw hasty conclusions, aberrant salience, self-esteem, and emotion regulation were the most frequently reported mechanisms associated with the emergence of psychotic experiences. Studies using the ESM also provided evidence for the role of stress sensitivity, in the development of psychotic symptoms. The ESM has widely been applied to studies investigating psychosis risk states, using a variety of protocols. Findings from this systematic review might inform future studies and indicate potential targets for interventions.
PURPOSE: An IL-1beta polypeptide and a polynucleotide encoding the same are provided to effectively enhance lysozyme activity. CONSTITUTION: An IL-1beta polypeptide derived from Sebastes schlegelii contains an amino acid of sequence number 2. A polynucleotide encoding IL-1beta polypeptide contains a base sequence of sequence number 1. A recombinant expression vector contains the polynucleotide. A composition for enhancing fish immunity contains the polypeptide as an active ingredient. [Reference numerals] (AA) Accumulated mortality rate(%)
BACKGROUND: Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers in the world. OSCC is a highly invasive lesion frequently having soaring morbidity as well as substantial mortality, attributed to resistance to therapy, metastasis, and recurrence driven by specific populations of cancer stem cells (CSC). The evidence of the association of expression of stem cell biomarker CD44 and metastatic potential of the tumor is inconclusive in OSCC and hence needs further evaluation.
OBJECTIVES: To determine the immunohistochemical expression of CD44 in OSCC and to find its association with lymph node metastasis and TNM staging.
MATERIALS AND METHODS: One hundred and five histologically proven cases of OSCC were studied. Histopathological parameters like depth of invasion, presence of lymph node metastasis, grading, and TNM staging were done according to the new AJCC staging criteria. Both intensity and proportion of CD44 expression were recorded.
RESULTS: The mean age observed in this study was 52.59 years with a male: female ratio of 1:3.76. Forty-nine cases (46.6%) showed a depth of invasion of more than 10 mm. Fifty-two out of one hundred and five cases (49%) had nodal involvement. TNM staging was 5.7%, 7.6%, 44.7%, and 42% for stages I, II, III, and IV, respectively. The majority of the cases (87.5%) showed CD44 expression in the tumor. There was a significant association between the CD44 expression and lymph node metastases (P < 0.001). Higher CD44 expression was seen in stages III and IV (P < 0.001).
CONCLUSION: CD44, a stem cell biomarker is significantly associated with higher TNM stage and lymph node metastases. This may be useful in predicting the tumor behavior in the small biopsy.
Uterine corpus endometrial carcinoma (UCEC) is becoming a main malignant cancer that threaten to women's health. Thymidine kinase 1 (TK1) is considering to be associated with tumorigenesis and development. Nevertheless, the function of TK1 in UCEC is still unclear. Herein, we analyzed the TK1 expression level in pan-cancer and found that TK1 was upregulated in a variety of cancers including UCEC. Patients of UCEC with high expression of TK1 were related to poor outcome. TK1 was also related to clinical stage, histologic grade and lymph node metastasis. Abnormal expression of TK1 in UCEC was related to promoter methylation while gene mutation was not frequent. TK1 and its associated genes appeared to be prominent in cell cycle and DNA replication, according to GO and KEGG analysis. Analysis of immune infiltration revealed a negative correlation between TK1 and CD8 + T cells, macrophages, and dendritic cells. In vitro experiments, TK1 knockdown resulted in the inhibition of proliferation, migration, invasion and EMT in UCEC cell lines.
The invention is directed to a substantially pure mammalian globin chain or heme-binding fragment thereof. The invention is further directed to recombinant DNA vectors capable of expressing at least one globin chain or substantially homologous variant thereof in yeast. The invention also relates to methods for expressing at least one globin chain or substantially homologous variant thereof in yeast. Expressed alpha-like globin and beta-like globin chains or variants thereof may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. Additionally, expressed gamma-globin chains may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. The invention also relates to methods for expressing hemoglobin or variants thereof in yeast where the heme is produced by the yeast and ligated to globins to form hemoglobin in vivo. The hemoglobin produced by the methods of the present invention may be used in applications requiring a physiological oxygen carrier such as in blood substitute solutions and as in plasma expanders or in applications requiring a physiological oxygen carrier.
The prognostic role of tumor cells in pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head with direct microscopic infiltration (DMI) or in close proximity (≤1 mm) to the resection margin (RM) remains unclear. This single-center, retrospective study included specimens from 75 patients who underwent oncological resection of pancreatic head PDAC between February 2013 and July 2020. Two pathologists independently re-measured the distance between tumors and the multiple RMs. The impact of RM involvement for DMI, tumor cells within ≤1 mm, in general, and for individual RMs on overall survival (OS) and development of distant pulmonary (PM) and hepatic (HM) metastasis was analyzed. DMI of RMs was significantly associated with a shorter OS (median 5 vs 19 months, P = .02). The presence of tumor cells within ≤1 mm of RMs yielded a negative impact on OS with a trend toward significance (median 9 vs 21 months, P = .09). DMI and tumor cells within ≤1 mm of the pancreatic transection margin (PRM), individually, had a significant negative impact on OS (median 4 vs 19 months and 6 vs 19 months, P < .05), but not for any other individual RM. RM involvement of ≤1 mm of only the vascular circumferential resection margin (VCRM) resulted in a shorter time to HM development (P = 0.05). DMI of the posterior circumferential resection margin (PCRM) and VCRM, individually, showed shorter time to PM (P < .05). Potential clinical considerations include extended intraoperative evaluation of the PRM (1 mm) and intensified preoperative prediction of R1 resection as a basis for neoadjuvant therapy.
Many biological mechanisms of aging well converge with radiation's biological effects. We used scientific insights from the field of aging to establish a novel hypoxic-hypercapnic environment (HHE) concept for radioprotection. According to this concept, HHE which possesses an anti-aging and longevity-promoting potential, should also act as a radiomitigator and radioprotector. As such, it might contribute greatly to the safety and wellbeing of individuals exposed to high levels of radiation, whether in planned events (e.g. astronauts) or in unplanned events (e.g. first responders in nuclear accidents).
Environmental conditions highly affect decomposition rates and therefore a forensic practitioner should consider context-specific information when estimating the post mortem interval (PMI). Traditional methods of collecting environmental data, however, are time-consuming and often impractical for large-scale studies or routine forensic investigations. This study developed an automated computer method by employing the technology of geographic information systems (GIS) and Python programming language to provide contextual information for bodies found outdoors in Greece. The generated coding script underwent testing on 95 bodies in various stages of decomposition, which were examined between the years 1999 and 2022 at the National and Kapodistrian University of Athens and the Forensic Medical Service of Thessaloniki. Using ArcGIS Pro software and publicly available online data, a multilayer map was developed. Individual layers included high-resolution aerial images and data on the European Nature Information System ecosystem type, the Köppen-Geiger climatic type, the population density, the elevation, and the slope. Additionally, 99 national weather stations and their corresponding meteorological data were integrated. By leveraging the geographical coordinates of the recovery site of each case and information about the decedent's disappearance and recovery dates, this script automatically generates details from each of the above layers. Additionally, it calculates the accumulated degree days (ADD) and accumulated humidity days (AHD) values by extracting data from the nearest weather station. The GIS-based approach enables rapid, objective, and reproducible taphonomic profile construction, which can greatly improve the reliability of PMI estimations. By utilizing this method, forensic practitioners can accurately evaluate environmental effects on decomposition, thus standardizing taphonomic profiling globally.
Provide and can realize the medical information browsing device that shows multiple windows high efficiency of readding sheet or diagnosis etc. of carrying out. The medical information browsing device of recording in embodiment has display part, display control unit, the first detection unit, adjustment part. Display control unit is presented in the display frame of display part multiple windows. When the first detection unit shows and makes the second window be also shown in display frame under the state of at least one the first window in display frame, the display condition of the viewing area based on the first window and the second window, judges and in display frame, whether has the region that can show the second window. Adjustment part is in the case of being judged to be not have to show the region of the second window, and can judgement adjust this display condition so that the first window and the second window are presented in display frame, is being judged as can adjust display condition in the situation that, adjusts display condition.
Systems, methods, computer storage media, and user interfaces are provided for automatically disassociating medical devices from patients. An indication that a medical device is associated with a patient and is online is received. A disruption in the communication with the medical device that has not been disassociated with the patient is identified. In embodiments, the disruption indicates the medical device has lost a wireless connection, is associated with a scheduled downtime, has been powered off, or is offline. Once it is determined that a predetermined period of time has elapsed since the disruption, the medical device is automatically disassociated from the patient. In embodiments, the medical device is retroactively re-associated to the patient if it is determined the medical device should not have been automatically disassociated from the patient.
Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.
Testosterone gel 1.62% was evaluated in a multi-center, randomized, double-blind, parallel-group, placebo-controlled study (182-day double-blind period) in 274 hypogonadal men with body mass index (BMI) 18 to 40 kg/m2 and 18 to 80 years of age (mean age 53.8 years). The patients had an average serum testosterone concentration of <300 ng/dL, as determined by two morning samples collected on the same visit. Patients were Caucasian 83%, Black 13%, Asian or Native American 4%. 7.5% of patients were Hispanic. 

Patients were randomized to receive active treatment or placebo using a rotation method utilizing the abdomen and upper arms/shoulders for 182 days. All patients were started at a daily dose of 40.5 mg (two pump actuations) testosterone gel 1.62% or matching placebo on Day 1 of the study. Patients returned to the clinic on Day 14, Day 28, and Day 42 for predose serum total testosterone assessments. The patient's daily dose was titrated up or down in 20.25 mg increments if the predose serum testosterone value was outside the range of 350 to 750 ng/dL. The study included four active testosterone gel 1.62% doses: 20.25 mg, 40.5 mg, 60.75 mg, and 81 mg daily. 

The primary endpoint was the percentage of patients with Cavg within the normal range of 300 to 1000 ng/dL on Day 112. In patients treated with testosterone gel 1.62%, 81.6% (146/179) had Cavg within the normal range at Day 112. The secondary endpoint was the percentage of patients, with Cmax above three pre-determined limits. The percentages of patients with Cmax greater than 1500 ng/dL, and between 1800 and 2499 ng/dL on Day 112 were 11.2% and 5.5%, respectively. Two patients had a Cmax >2500 ng/dL on Day 112 (2510 ng/dL and 2550 ng/dL, respectively); neither of these 2 patients demonstrated an abnormal Cmax on prior or subsequent assessments at the same dose. 

Patients could agree to continue in an open-label, active treatment maintenance period of the study for an additional 182 days. 

Dose titrations on Days 14, 28, and 42 resulted in final doses of 20.25 mg to 81 mg on Day 112 as shown in Table 5. 

Figure 3 summarizes the pharmacokinetic profile of total testosterone in patients completing 112 days of testosterone gel 1.62% treatment administered as a starting dose of 40.5 mg of testosterone (2 pump actuations) for the initial 14 days followed by possible titration according to the follow-up testosterone measurements.

Figure 3: Mean (±SD) Steady-State Serum Total Testosterone Concentrations on Day 112 

Efficacy was maintained in the group of men that received testosterone gel 1.62% for one full year. In that group, 78% (106/136) had average serum testosterone concentrations in the normal range at Day 364. Figure 4 summarizes the mean total testosterone profile for these patients on Day 364.

Figure 4: Mean (±SD) Steady-State Serum Total Testosterone Concentrations on Day 364 

The mean estradiol and DHT concentration profiles paralleled the changes observed in testosterone. The levels of LH and FSH decreased with testosterone treatment. The decreases in levels of LH and FSH are consistent with reports published in the literature of long-term treatment with testosterone.
All patients will receive a pre-emptive skin care regimen during panitumumab therapy to reduce skin toxicity. Treatment cycles will be repeated every 14 days (2 weeks). During each treatment, panitumumab will be administered first, then carboplatin, then gemcitabine. All drugs will be administered according to standard guidelines. Patients will be re-evaluated for response after completion of 3 cycles (6 weeks) of treatment. Patients with objective response or stable disease will continue treatment. Subsequent re-evaluations will occur every 6 weeks. Patients will continue treatment with all three drugs until tumor progression, or until unacceptable toxicity occurs. If patients experience toxicity caused by gemcitabine/carboplatin and are continuing to benefit from treatment, panitumumab can be continued as a single agent (at the same dose and schedule), at the discretion of the investigator, until disease progression occurs.
Sulfamethoxazole and Trimethoprim Injection is contraindicated in pediatric patients younger than two months of age because of the potential risk of bilirubin displacement and kernicterus [see Contraindications (4)].

Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and low birth weight infants in the neonatal intensive care unit who received benzyl alcohol as a preservative in infusion solutions. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were

0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

When prescribing Sulfamethoxazole and Trimethoprim Injection in pediatric patients consider the combined daily metabolic load of benzyl alcohol from all sources including Sulfamethoxazole and Trimethoprim Injection (Sulfamethoxazole and Trimethoprim Injection contains 10 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Warnings and Precautions (5.7)].
The invention discloses a preparation method of a simvastatin hydroxy acidified matter. The preparation method is simple, raw materials are easy to obtain, and the preparation method is conductive to industrial production. The invention further discloses a composition of the simvastatin hydroxy acidified matter, all auxiliary components in the composition are easy to obtain, and the composition is conductive to industrialization. The invention further discloses a preparation method of the composition of the simvastatin hydroxy acidified matter, the requirements of the preparation method for process conditions are not high, and the preparation method is easy to operate. The invention also discloses an application of the simvastatin hydroxy acidified matter in preparation of medicaments for treating hyperlipidemia. The toxicity of the simvastatin hydroxy acidified matter is significantly reduced, and the simvastatin hydroxy acidified matter can be used for treating hyperlipidemia without metabolism in vivo.
Galantamine hydrobromide is a medication that is approved for the treatment of symptoms of Alzheimer's disease. In accordance with international guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety. This is a multi-center, open-label (all people involved know the identity of the intervention), observational study (individuals are observed or certain outcomes are measured - no attempt is made to affect the outcome) to collect information regarding the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease. Patients who have been prescribed galantamine hydrobromide as initial treatment with this type of medication for their Alzheimer's disease or who have failed previous treatment with similar medication of this type for their Alzheimer's disease will receive galantamine hydrobromide for 6 months. The individual physicians responsible for the treatment of Alzheimer's disease will administer galantamine hydrobromide at doses appropriate for each patient and will continue to oversee their care. No medication will be supplied by the sponsor of this study. Safety evaluations (incidence of adverse events, physical exams, vital signs and laboratory tests) will be performed throughout the study. Effectiveness will be determined using standard tests and rating scales to assess mental status, functioning, thinking, behavior, judgment and language (Neuropsychiatric Inventory, \[NPI\], Mini Mental Status Exam \[MMSE\] and Clinical Global Impression-Caregiver \[CGI-Caregiver\]). Assessments will be conducted monthly for the first 3 months and at the end of 6 months of treatment. Galantamine hydrobromide treatment should be discontinued if there is no further indication of effectiveness. At the end of the study, the treating physician may continue treatment with galantamine hydrobromide in responding patients as appropriate. The study hypothesis is that galantamine hydrobromide will be effective in treating the symptoms associated with Alzheimer's disease and is safe and well-tolerated. Observational study -No investigational drug administered
Up to 50% of patients with symptoms of heart failure have a preserved left ventricular ejection fraction (HFpEF syndrome). Current therapy for systolic heart failure is targeted at inducing vasodilation and counteracting neuro-endocrine activation. There is a lack of a corresponding evidence base for the treatment of HEpEF. We have previously shown that perhexiline, an agent that increases the efficiency of energy production by shifting substrate utilization from free fatty acids towards glucose, was highly effective in improving exercise capacity, symptoms and cardiac function in patients with systolic heart failure. We have also recently shown that energy deficiency plays a major role in the pathophysiology of HFpEF. In this proposal we therefore aim to investigate the effectiveness of perhexiline in 70 HFpEF patients, in a 3 month randomised, double-blind, controlled trial. An interim analysis is planned after 20 patients.
During the dose-escalation stage, an accelerated titration design (ATD) will be utilized for the first three lower dose groups (0.06, 0.12 and 0.18 mg/m\^2). The conventional "3+3" dose escalation method will be used for the subsequent dose groups. The entire duration of 21 days after the first dose of ZG0895.HCl is defined as the dose-limiting toxicity (DLT) observation period.
1478759 Forming outlet passageways in pills ALZA CORP 30 Oct 1975 [18 Nov 1974] 45037/75 Heading B2E  Outlet passageways 13 4-2000 Á in diameter are formed in pills 10 by charging the pills to hopper 33 from which they drop by gravity into slots 32 of rotating feed wheel 28. Wheel 28 carries the pills along a circular path at a velocity predetermined by motor 25 to passageway forming station 37. Optical tracking mechanism 17 sweeps repeatedly 1 of the arc of the circular path along which the pills are moved and tracking is accomplished by rotational oscillation of mount 57 and tracking mirror 55. Tracking mechanism 17 and wheel 28 are synchronised in velocity because both are driven by motor 25. During tracking a magnetic sensor triggers firing of laser 16. Laser beam 16 is directed on to the moving pills. The energy of beam 47 is absorbed by wall 12  thus forming passageway 13. Core 13 may comprise an active agent e.g. a drug and comprises an osmotically effective solute, e.g. an organic salt or a sugar. Wall 12 may be of cellulose acetate, plasticised cellulose triacetate, agar acetate, amylose triacetate, #-glucan triacetate, acetaldehyde trimethylacetate, cellulose acetate ethyl carbonate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate dimethylaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate, chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulphonate, cellulose ethers, poly(vinyl methyl) ether copolymers, cellulose acetate octoate, methyl cellulose, polyurethanes, hydrolysed polyvinylacetate and hydroxylated ethylene-vinyl acetate copolymer.